Bone and soft tissue tumors, constitute a heterogeneous group of neoplasms that frequently affect the young. These tumors are highly aggressive, often metastasizing early in the disease's progression, posing a significant challenge to orthopedic oncologists. Treatment strategies for these tumors have evolved, with a mainstay approach combining surgery, chemotherapy, and more recently, the introduction of targeted therapies and immunotherapy. Over the past decade, there have been significant advancements in the molecular understanding of these tumors, leading to the development of innovative therapeutic strategies that hold promise for improving patient outcomes and potentially modifying the prognosis of these malignancies.This study encompassed a total of 10 articles, comprising 4 original research articles, 5 review articles, and 1 case report.
RNA PRR7-AS1 in the development of bone sarcoma and evaluated its potential as a therapeutic target. The team discovered that PRR7-AS1 interacts with the protein RNF2, thereby inhibiting the translation of the downstream gene MTUS1, which in turn promotes the proliferation and migration of bone sarcoma cells. Furthermore, the researchers found that the knockdown of PRR7-AS1 significantly suppressed the in vitro proliferation and the in vivo growth and metastasis of bone sarcoma cells. These findings underscore the oncogenic role of PRR7-AS1 in bone sarcoma and suggest its potential as a novel target for diagnosis and treatment.
that was inoperable and successfully treated with Denosumab. The case involved a 49year-old male who had undergone two surgeries for GCTB in the right proximal ulna.A CT-guided needle biopsy revealed rapid growth and high 18F-FDG uptake, though no histological signs of malignancy were present. Given that the lung lesion was not surgically removable, Denosumab was administered. After 18 months of initial treatment with Denosumab, there were no symptoms or signs of tumor growth. While the long-term efficacy and safety of Denosumab remain to be determined, the authors posit that it may represent a viable treatment option for patients with non-resectable pulmonary GCTB. Osumi and colleagues' study on the role of proteoglycan synthesis genes in osteosarcoma stem cells offers valuable insights into cellular mechanisms that could be targeted for therapy. Understanding the pathways that govern the self-renewal and differentiation of osteosarcoma stem cells is essential for developing targeted therapies to effectively counteract tumor recurrence and metastasis. These therapies are designed to disrupt specific molecular pathways driving tumor growth, offering a more personalized approach to treatment.


